Big Breather For Indian Pharma

New York: Because of the importance of India’s pharmaceuticals to US healthcare, those exports will get a reprieve from President Donald Trump’s reciprocal tariffs, according to the White House.

The US is the largest importer of pharmaceuticals from India, bringing in products in the category worth $8.73 billion during the 2024 fiscal year, according to statistics cited by the India Brand Equity Foundation (IBEF).IBEF said 31.5 per cent of India’s pharmaceutical exports went to the US.

The White House factsheet issued on Wednesday after Trump’s announcement of 26 per cent reciprocal tariffs on imports from India said that pharmaceuticals were exempt. Indian drugs, especially the generics, help hold down the costs of the US healthcare system, which is already one of the most expensive in the world.